Related Experiment Video
Updated: Jun 9, 2025

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Clinical features of Chagas disease progression and severity
Maria Carmo P Nunes1, Caryn Bern2, Eva H Clark3
1Hospital das Clínicas and Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Insights
Chagas disease causes cardiomyopathy and neurological issues, impacting morbidity and mortality in Latin America. This review details its clinical spectrum, progression factors, and prognostic indicators.
Area of Science:
- Cardiology
- Neurology
- Infectious Diseases
Background:
- Chagas disease is a leading cause of non-ischemic cardiomyopathy and mortality in Latin America.
- It presents a wide clinical spectrum, affecting cardiac and neurological functions.
- Disease progression is influenced by treatment, host-parasite dynamics, and social factors.
Purpose of the Study:
- To review the clinical presentations of Chagas disease.
- To explore the spectrum of Chagas cardiomyopathy and neurological manifestations.
- To analyze factors influencing disease progression and mortality.
Main Methods:
- Literature review of Chagas disease.
- Analysis of clinical presentations and prognostic factors.
- Investigation of treatment, host-parasite interactions, and social determinants.
Main Results:
- Chagas cardiomyopathy severity, particularly left ventricular dysfunction, dictates prognosis.
- Neurological effects include cardioembolic strokes and cognitive impairments.
- Progression is multifactorial, involving anti-parasitic treatment, host-parasite interactions, and social determinants.
Conclusions:
- Chagas disease presents significant cardiac and neurological morbidity.
- Understanding prognostic factors is crucial for managing this fatal illness.
- Further research into influencing factors can improve patient outcomes.
Abstract:
Chagas disease, the most common form of nonischaemic cardiomyopathy globally, is one of the leading causes of morbidity and mortality in Latin America. Chagas cardiomyopathy has a wide clinical spectrum and prognosis, which is primarily determined by the severity of left ventricular dysfunction. Chagas disease also affects the brain, particularly manifesting as cardioembolic strokes and cognitive impairments. Disease progression is influenced by various factors such as anti-parasite treatments, host-parasite interactions, and other determinants. This review explores Chagas disease, covering clinical presentations, the range of severity of Chagas cardiomyopathy, and neurological manifestations. We investigate factors that influence the progression of cardiomyopathy, including anti-parasitic treatments, interactions between hosts and parasites, and the influence of social determinants on the course of the disease. This review analyses key prognostic factors associated with the progression and mortality of Chagas cardiomyopathy, offering insights into this potentially fatal illness.
Related Concept Videos
Endocarditis II: Clinical features and Diagnostic Tests
Myocarditis II: Clinical features and Diagnostic Tests
Pathophysiology of Heart Failure
Heart Failure IV: Classification and Diagnostic Evaluation
Myocarditis I: Introduction
Pericarditis II: Clinical features and Diagnostic Tests

